deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT04773951

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Humanized Monoclonal Antibody Specific to B- and T- Lymphocyte Attenuator, BTLA (JS004) Injection in Patients With Advanced Solid Tumors

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Melanoma Renal Carcinoma Urothelial Carcinoma
Interventions JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Updated 6 times since 2021 Last updated: Aug 23, 2021 Started: Apr 12, 2021 Primary completion: Feb 29, 2024 Completion: Aug 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Melanoma and Renal Carcinoma and is currently ongoing. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshotNot Yet Recruiting~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshotRecruiting~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotRecruiting~Oct 2024 – present · 23 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Oct 2024 — Present [monthly]

    Unknown PHASE1

    Status: Recruiting → Unknown

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Sep 2021 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Mar 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Junshi Bioscience Co., Ltd.
Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations